Loyal raises $100 million for dog longevity drugs – Bizwomen – The Business Journals

When I saw the headline that Loyal raised $100 million to develop drugs that could extend our dogs’ lives, I had to know more. This isn’t some supplement company promising miracles—Loyal is a biotech firm conducting FDA-regulated clinical trials on compounds designed to target the biological mechanisms of aging in dogs.

After losing Cooper at just 9 years old, I’ve spent countless hours reading longevity research. What Loyal is doing represents the first serious attempt to bring science-backed interventions to veterinary medicine that could actually slow down aging, not just treat age-related diseases after they appear.

What Loyal Is Actually Developing

Loyal has two lead drug candidates in development, both targeting different aspects of canine aging. LOY-001 is designed for large and giant breed dogs, which age faster than small dogs—a Great Dane’s lifespan averages 7-10 years while a Chihuahua can live 14-17 years. LOY-002 targets cellular aging mechanisms across all dog sizes.

The $100 million Series B funding round, led by Khosla Ventures and Baillie Gifford, brings Loyal’s total funding to over $125 million. That’s real money backing real science, not internet hype.

LOY-001: The IGF-1 Inhibitor

LOY-001 works by reducing levels of IGF-1 (insulin-like growth factor 1), a hormone that drives growth but also appears to accelerate aging in large dogs. Research has consistently shown that smaller dogs live longer partly because they have lower IGF-1 levels throughout their lives.

Think of it this way: a Great Dane grows from puppy to 150+ pounds in about 18 months. That explosive growth comes at a metabolic cost. LOY-001 is administered as an injection every 3-6 months and aims to dial back that accelerated aging process in dogs over 40 pounds.

Loyal has already completed multiple clinical trials showing LOY-001 is safe and well-tolerated. They’re now in discussions with the FDA for conditional approval, which could come as early as 2026.

LOY-002: The Cellular Aging Target

LOY-002 is a daily pill that targets fundamental aging pathways at the cellular level. While Loyal hasn’t disclosed the exact mechanism, the approach focuses on cellular senescence—the accumulation of “zombie cells” that stop dividing but don’t die, instead secreting inflammatory compounds that damage surrounding tissue.

This drug is intended for all adult dogs, regardless of size, and represents a broader approach to longevity. It’s earlier in development than LOY-001 but could have wider application if it proves effective.

Comparing Loyal’s Drug Candidates

Feature	LOY-001	LOY-002
Target Dogs	Large and giant breeds (40+ lbs)	All adult dogs, all sizes
Mechanism	Reduces IGF-1 levels	Targets cellular senescence
Administration	Injection every 3-6 months	Daily pill
Development Stage	Late-stage, FDA discussions ongoing	Earlier development phase
Potential Approval	Possibly 2026	Timeline not yet announced
Expected Benefit	Could add 1+ year to lifespan	Healthspan extension, lifespan TBD

Why Size Matters in Dog Aging

The size-lifespan relationship in dogs is one of the most dramatic examples we have in mammals. Within a single species, you have animals ranging from 4-pound Yorkies to 200-pound Mastiffs—and the small ones live nearly twice as long.

This is backwards from what we see across species. Elephants live longer than mice. Whales live longer than rabbits. Larger animals typically have slower metabolic rates and longer lifespans. But within dogs, the opposite is true.

Research published in Aging Cell found that large dogs age at an accelerated pace from puppyhood onward. Their cells show markers of aging earlier, they develop age-related diseases sooner, and they die younger. A 7-year-old Great Dane is biologically equivalent to a 12-year-old Chihuahua.

If Cooper had been 30 pounds instead of 75, he might have had 5 more years. That thought still hurts.

What This Means for Dog Owners Now

Let’s be clear: these drugs aren’t available yet. LOY-001 might launch in 2026 if FDA discussions go well, but that’s still conditional. LOY-002 is further out. You can’t order either from your vet today.

But what you can do is the boring, proven stuff that matters:

• Keep your dog lean. Obesity is the single biggest controllable factor reducing lifespan. A 14-year Purina study found that lean dogs lived 1.8 years longer than their overweight littermates.
• Feed high-quality food. Look for high-protein dog food with named meat sources as the first ingredient, not corn or wheat.
• Exercise matters. Daily walks aren’t optional. Mental stimulation through puzzle toys and training keeps their brains healthy too.
• Dental health is longevity. Periodontal disease creates chronic inflammation that affects the whole body. Brush teeth regularly with enzymatic toothpaste or use dental chews.
• Catch problems early. Annual bloodwork starting at age 7 (earlier for giant breeds) can detect kidney, liver, or thyroid issues before symptoms appear.

These aren’t sexy. They won’t make headlines. But they work right now, today, for your dog.

The Science Behind Longevity Drugs

What Loyal is doing isn’t unprecedented—it’s translating decades of aging research from lab animals to dogs. Reducing IGF-1 signaling extends lifespan in worms, flies, mice, and even some fish. Clearing senescent cells has reversed age-related dysfunction in mice.

Dogs are the perfect proving ground for longevity interventions because they age faster than humans but slower than mice, they live in our environments (not sterile cages), and they get the same age-related diseases we do—cancer, arthritis, kidney disease, dementia.

If these drugs work in dogs, they validate the underlying biology in a way that mouse studies never could. And yes, the ultimate goal is to develop similar therapies for humans. But I’m not thinking about that. I’m thinking about the 8-year-old Labs and 6-year-old Bernese Mountain Dogs who might get more years with their people.

What About Side Effects?

Any drug has risks. LOY-001 reduces IGF-1, which is important for muscle maintenance and wound healing. Loyal’s trials haven’t shown significant adverse effects, but we’re talking about healthy dogs taking a preventive medication for years. Long-term data doesn’t exist yet because the drug is new.

I’d want to see at least 3-5 years of post-market safety data before considering it for my own dog, especially for a medication taken over many years. That’s the researcher in me talking. The dog mom who lost Cooper too young? She understands why people will line up the day it’s approved.

The Business Case for Dog Longevity

That $100 million isn’t charity. Investors expect returns. The U.S. pet supplement market alone is worth $1.4 billion annually, and most supplements have minimal evidence behind them. A proven longevity drug with FDA approval would be in a category of one.

If LOY-001 costs $50-100 per month (pure speculation—Loyal hasn’t announced pricing), and just 10% of the 50+ million dogs over 40 pounds in the U.S. use it, that’s billions in annual revenue. The market opportunity is massive.

This is why serious biotech investors are involved. Khosla Ventures backed Impossible Foods and Affirm. Baillie Gifford was an early Tesla investor. These aren’t pet industry insiders taking a flyer—they’re sophisticated investors who think Loyal can become a major pharmaceutical company.

When Could These Drugs Be Available?

Loyal is pursuing conditional approval for LOY-001 under the FDA’s Minor Use Minor Species (MUMS) pathway. This is the same route used for other veterinary drugs with limited market size but clear medical benefit. Conditional approval allows marketing while additional effectiveness data is collected.

If approved in 2026, LOY-001 would initially be available through veterinarians only, likely requiring an exam and bloodwork to establish baseline health. You won’t be ordering it online.

LOY-002 is further behind, with no announced timeline for approval. It could be 2028-2030 or later before it reaches the market.

Should You Change Anything Now?

No. Keep doing what works. Feed well, exercise daily, maintain a healthy weight, see your vet regularly. Those fundamentals matter more than any future drug.

But if you have a large breed dog, stay informed. Follow Loyal’s progress. Ask your vet about LOY-001 when it launches. Make an informed decision based on the data available at that time, not hope or fear.

I would have given anything for an extra year with Cooper. If a proven drug becomes available that could give other dogs that time, that’s worth paying attention to.

Frequently Asked Questions

Can I sign up my dog for Loyal’s clinical trials?

Loyal isn’t currently recruiting for LOY-001 trials, as they’re in FDA discussions for approval. They may recruit for LOY-002 trials in the future. Check their website at loyal.com for updates, as trial recruitment is announced there first. Be aware that clinical trials have strict eligibility criteria including age, breed, weight, and health status.

Will pet insurance cover longevity drugs?

Unknown. Most pet insurance policies cover treatment for illness or injury, not preventive medications or supplements. Since LOY-001 would be prescribed to healthy dogs to prevent age-related decline rather than treat existing disease, it might not be covered. This will likely vary by insurer and policy. Check with your specific insurance provider when the drug becomes available.

Are there any supplements that work like these drugs?

No. There are no supplements with comparable mechanisms or evidence. Some owners give resveratrol or omega-3 supplements for dogs based on longevity research in other species, but the evidence in dogs is limited. Nothing available over-the-counter targets IGF-1 signaling the way LOY-001 does or has been tested in controlled trials for lifespan extension.

Would these drugs work for small dogs too?

LOY-001 is specifically designed for large and giant breeds because they have elevated IGF-1 levels and shortened lifespans compared to small dogs. Small dogs already have naturally low IGF-1, so reducing it further might not provide benefit and could potentially cause harm. LOY-002, on the other hand, is being developed for all dog sizes since cellular senescence affects aging across the board.

How much could these drugs actually extend a dog’s life?

Loyal estimates that LOY-001 could add at least one year to the lifespan of large and giant breed dogs, potentially more. That’s based on the magnitude of IGF-1 reduction and comparable interventions in other species. The honest answer is we won’t know for certain until years of real-world data accumulate after approval. The goal isn’t just lifespan but healthspan—more years of good quality life, not just extending frailty.